您当前位置: 首页 > 国际期刊-IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY期刊投稿发表详细信息
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY Q2

  • 期刊收录:
  • SCIE
  • Scopus
基本信息
  • 期刊ISSN:

    0892-3973

  • 期刊简拼:

    IMMUNOPHARM IMMUNOT

  • 年发文章数:

    59

  • E-ISSN:

    1532-2513

  • Gold OA文章占比

    4.26%

  • 研究文章占比:

    86.44%

  • 是否OA:

    No

  • Jcr分区:

    Q2

  • 中科院分区:

    4区

出版信息
  • 出版商:

    Informa Healthcare

  • 涉及研究方向:

    医学-毒理学

  • 出版国家:

    UNITED STATES

  • 出版语言:

    English

  • 出版周期:

    Quarterly

  • 出版年份:

  • 2023-2024最新影响因子:2.9
  • 自引率:0.00%
  • 五年影响因子:3.2
  • JCI期刊引文指标:0.71
  • h-index:42
  • CiteScore:5.40

期刊简介

The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.

The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.

With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.

Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).

《IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY》期刊已被查看:
期刊简写:IMMUNOPHARM IMMUNOT

此期刊被最新的JCR期刊SCIE收录

期刊信息

  • 通讯地址
  • TAYLOR & FRANCIS INC, 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, USA, PA, 19106
  • 中国科学院《国际期刊预警名单(试行)》名单
  • 2024年02月发布的2024版:不在预警名单中
    2023年01月发布的2023版:不在预警名单中
    2021年12月发布的2021版:不在预警名单中
    2020年12月发布的2020版:不在预警名单中
    此期刊被最新的JCR期刊SCIE收录
  • 审稿速度
  • 收录数据库
  • 是否oa
  • 研究方向
  • 偏慢,4-8周
  • SCIE,Scopus
  • No
  • 医学-毒理学

分区信息

中科院分区
  • 大类学科
  • 分区
  • 小类学科
  • Top期刊
  • 综述期刊
  • 医学
  • 4区
  • TOXICOLOGY
    毒理学
    IMMUNOLOGY
    免疫学
    PHARMACOLOGY & PHARMACY
    药学
WOS分区等级:2区
  • 版本
  • 按学科
  • 分区
  • 影响因子
  • WOS期刊SCI分(2023-2024年最新版)
  • IMMUNOLOGY
    PHARMACOLOGY & PHARMACY
    TOXICOLOGY
  • Q2
  • 2.9
IF值(影响因子)趋势图
年发文量趋势图
自引率趋势图
中科院分区

常见问题

  • sci四区价格多少算合理?

     一篇sci4区是sci里最便宜的了 价格一般在3-4左右,如果有人告诉你几k就能发或者五位数出头,个人建议谨慎一点,不能因为贪小便宜吃大亏如果四区就能满足学